Unique ID issued by UMIN | UMIN000013079 |
---|---|
Receipt number | R000015259 |
Scientific Title | A retrospective analysis of the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer |
Date of disclosure of the study information | 2014/02/05 |
Last modified on | 2014/02/05 12:22:49 |
A retrospective analysis of the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer
A retrospective analysis of the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer
A retrospective analysis of the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer
A retrospective analysis of the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer
Japan |
ovarian, fallopian tubal, primary peritneal, uterus corpus cancer
Obstetrics and Gynecology |
Malignancy
NO
We evaluate the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer. If the complete surgery contribute to good prognosis and less adverse effect for each patients, we can had one optional treatment for advanced ovarian, fallopian tubal, primary peritneal, uterus corpus cancer.
Safety,Efficacy
Progression free survival,toxicity
overall survival
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Device,equipment |
operation,chemotherpy
25 | years-old | <= |
80 | years-old | > |
Female
1)Patients with a histological diagnosis of ovarian cancer (including fallopian tube, or primary peritoneal carcinoma) and uterus corpus cancer
2)Patients who are 20 years old or older and younger than 80 years old at the enrollment
3)Performance status:ECOG 0-2
4)Adequate bone marrow, renal, and hepatic function
5)Patients who are expected to survive more than 3 months.
6)Patients who have signed an approved informed consent.
1)Patients who have a history of hypersensitivity to gemcitabine and irinotecan.
2)Patients with active infection
3)Patients with severe complications (Heart disease, uncontrolleddiabetes, malignant hypertension, or bleeding tendency)
4)Patients with other cancer within the past 5 years
5)Patients with myocardial infarction within 6 months or angina attack.
6)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.
50
1st name | |
Middle name | |
Last name | Shinichi Tate , M.D. |
Chiba University Hospital
Department of Gynecology
1-8-1 Inohana Chuo Chiba Japan
043-222-7171
state@faculty.chiba-u.jp
1st name | |
Middle name | |
Last name | Shinichi Tate , M.D. |
Chiba University Hospital
Department of Gynecology
1-8-1 Inohana Chuo Chiba Japan
043-222-7171
state@faculty.chiba-u.jp
School of Medicine, Chiba University
none
Other
NO
2014 | Year | 02 | Month | 05 | Day |
Unpublished
Open public recruiting
2014 | Year | 02 | Month | 05 | Day |
2014 | Year | 02 | Month | 05 | Day |
2014 | Year | 02 | Month | 05 | Day |
2014 | Year | 02 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015259
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |